morteza naghavi, m.d. founder society for heart attack prevention and eradication (shape) shape...

Download Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart

If you can't read please download the document

Upload: griffin-mcbride

Post on 22-Dec-2015

229 views

Category:

Documents


3 download

TRANSCRIPT

  • Slide 1
  • Slide 2
  • Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart Attack & Stroke) based on the Detection and Treatment of Subclinical Atherosclerosis (Hidden Plaque Build-up in Coronary and Carotid arteries)
  • Slide 3
  • The Problem
  • Slide 4
  • > 15 Million Heart Attacks Each Year Source: World Heart Federation The AEHA 2005 VP Summit
  • Slide 5
  • Unpredicted
  • Slide 6
  • In >50% of victims, the first symptom of asymptomatic atherosclerosis is a sudden cardiac death or acute MI.
  • Slide 7
  • Men Women 010203040506070 Patients Diagnosed with CHD (%) Murabito et al Circulation 1993 Sudden Cardiac Death or Acute MI as Initial Presentation of CHD 62% 42%
  • Slide 8
  • Of 136,905 patients hospitalized with CAD, 77% had normal LDL levels below 130 mg/dl Modified from Sachdeva et al. AHJ, Vol 157, 111-117 Jan 2009 Chapter 1: Preventive Cardiology; the SHAPE of the Future in Naghavi et al. Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment. Humana Press, 2009
  • Slide 9
  • Modified from Sachdeva et al. AHJ, Vol 157, 111-117 Jan 2009 Chapter 1: Preventive Cardiology; the SHAPE of the Future in Naghavi et al. Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment. Humana Press, 2009 Of 136,905 patients hospitalized with CAD, 45.4% had normal HDL levels above 40 mg/dl
  • Slide 10
  • Of 136,905 patients hospitalized with CAD, 61.8% had normal triglyceride levels below 150 mg/dl Modified from Sachdeva et al. AHJ, Vol 157, 111-117 Jan 2009 Chapter 1: Preventive Cardiology; the SHAPE of the Future in Naghavi et al. Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment. Humana Press, 2009
  • Slide 11
  • Slide Source: Lipids Online www.lipidsonline.org 1998 2002. 222 patients with 1 st acute MI, no prior CAD, no DM. Men 20% Goal LDL
  • Slide 12
  • Relying on risk factors of atherosclerosis (i.e. cholesterol & blood pressure) mislead physicians and patients. A direct assessment of atherosclerosis is needed. CONCLUSION:
  • Slide 13
  • Sir Winston Churchill, 91 Sir Winston Churchill, 91 Jim Fixx, 53 Jim Fixx, 53 Who Has More Cardiovascular Risk Factors?
  • Slide 14
  • Philip Alexander Poole-Wilson death with 66 years March 4, 2009 Two weeks after Update in Cardiology In Davos Helmut Drexler death with 58 years Unexpected Sudden Death of Famous Cardiologists
  • Slide 15
  • Status Quo IS Unacceptable Bottom Line:
  • Slide 16
  • CVD Genotyping? Naghavi et al. Circulation. 2003;108:1664 ~50% Apparently Healthy People (New) ~50% CHD Patients (Recurrent)
  • Slide 17
  • CVD Genotyping? Naghavi et al. Circulation. 2003;108:1664 ~50% Apparently Healthy People (New) ~50% CHD Patients (Recurrent)
  • Slide 18
  • Naghavi et. al. Circulation Journal Vol108, No14; October 7, 2003 The Vulnerable Patient Consensus Statement Preceding the SHAPE Initiative
  • Slide 19
  • Naghavi et. al. Circulation Journal Vol108, No14; October 7, 2003 The Vulnerable Patient Consensus Statement Preceding the SHAPE Initiative
  • Slide 20
  • First SHAPE Symposium
  • Slide 21
  • SHAPE Task Force Meeting
  • Slide 22
  • SHAPE Guidelines Published
  • Slide 23
  • Slide 24
  • Existing Guidelines (Status Quo): Screen for Risk Factors of Atherosclerosis Treat Risk Factors of Atherosclerosis The SHAPE Guidelines: Screen for Atherosclerosis (the Disease) Regardless of Risk Factors Treat based on the Severity of the Disease and its Risk Factors SHAPE v.s. Status Quo
  • Slide 25
  • Slide 26
  • Slide 27
  • Based on the paper by Pepe e. al. Am J Epidemiol 2004; 159:882-890. ROC Curve, its AUC and Corresponding Odds Ratio hs-CRP LDL HDL Smoking Hypertension Diabetes etc. Risk Factors
  • Slide 28
  • Slide 29
  • Based on the paper by Pepe e. al. Am J Epidemiol 2004; 159:882-890. ROC Curve, its AUC and Corresponding Odds Ratio hs-CRP LDL HDL Smoking Hypertension Diabetes etc. CAC +FRS IMT+FRS Structural Risk Factors
  • Slide 30
  • Slide 31
  • Based on the paper by Pepe e. al. Am J Epidemiol 2004; 159:882-890. ROC Curve, its AUC and Corresponding Odds Ratio hs-CRP LDL HDL Smoking Hypertension Diabetes etc. CAC +FRS IMT+FRS Structural Risk Factors Combined structural & functional?
  • Slide 32
  • Slide 33
  • Slide 34
  • 1: No history of angina, heart attack, stroke, or peripheral arterial disease. 2: Population over age 75y is considered high risk and must receive therapy without testing for atherosclerosis. 3: Must not have any of the following: Chol>200 mg/dl, blood pressure >120/80 mmHg, diabetes, smoking, family history, metabolic syndrome. 4: Pending the development of standard practice guidelines. 5: High cholesterol, high blood pressure, diabetes, smoking, family history, metabolic syndrome. 6: For stroke prevention, follow existing guidelines.
  • Slide 35
  • Some of the Members of the SHAPE Task Force (left to right): Drs Budoff, Falk, Rumberger, Naghavi, Fayad, Hecht, and Berman
  • Slide 36
  • Current National Preventive Care Reimbursement Policies Do Not Match the Burden of the Problem Inadequate & Disproportionate
  • Slide 37
  • Slide 38
  • Why do we screen for asymptomatic cancers but ignore asymptomatic CVD?
  • Slide 39
  • $1000 for # 2 Killer
  • Slide 40
  • Slide 41
  • Slide 42
  • Slide 43
  • Number (per year) Estimated Impact of SHAPE (Sensitivity Analysis Range) Estimated Change in Cost CVD Deaths910,60010% (5%-25%) ($1.2 b) MI (prevalence)7,200,000 25% (5%-35%) ($18.0 b) Chest Pain Symptoms (ER visits)6,500,000 5% (2.5%-25%) ($4.1 b) Hospital Discharge for Primary Diagnosis of CVD6,373,000 10% (5%-25%) $3.8 b Hospital Discharge for Primary Diagnosis of CHD970,000 10% (5%-25%) ($9.9 b) Cholesterol Lowering Therapy 50 % (50%-65%) 8.00 b CV Imaging8,700,000 10% (5%-25%) $358 m Angiography6,800,000 15% - CTA (2.5%-25%) $600 m PCI (percutaneous coronary interventions per year)657,000 10% (5%-50%) ($580 m) CABS (coronary artery bypass surgeries per year)515,000 5% (2.5%-50%) ($672 m) Total in Cost ($21.5 b) Cost Effectiveness of the SHAPE Guidelines
  • Slide 44
  • Slide 45
  • poly pills
  • Slide 46
  • WWW.SHAPESOCIETY.ORG
  • Slide 47
  • The SHAPE Textbook Released at American College of Cardiology Conference